D.A. Davidson & CO. trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 2.1% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 492,907 shares of the company’s stock after selling 10,382 shares during the quarter. Johnson & Johnson makes up 1.2% of D.A. Davidson & CO.’s portfolio, making the stock its 10th biggest holding. D.A. Davidson & CO.’s holdings in Johnson & Johnson were worth $59,809,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. raised its holdings in shares of Johnson & Johnson by 4.7% in the first quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock worth $22,476,102,000 after acquiring an additional 7,853,141 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Johnson & Johnson by 1.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 30,303,272 shares of the company’s stock worth $3,676,999,000 after acquiring an additional 541,338 shares during the last quarter. Fisher Asset Management LLC raised its holdings in shares of Johnson & Johnson by 3.8% in the second quarter. Fisher Asset Management LLC now owns 13,118,604 shares of the company’s stock worth $1,591,811,000 after acquiring an additional 478,982 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Johnson & Johnson by 4.5% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,978,198 shares of the company’s stock worth $1,089,415,000 after acquiring an additional 387,504 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Johnson & Johnson by 9.5% in the first quarter. Dimensional Fund Advisors LP now owns 7,552,034 shares of the company’s stock worth $967,793,000 after acquiring an additional 654,350 shares during the last quarter. 66.06% of the stock is owned by institutional investors.

In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 7,899 shares of the business’s stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the completion of the sale, the chief accounting officer now owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Alex Gorsky sold 264,465 shares of the business’s stock in a transaction dated Friday, November 16th. The shares were sold at an average price of $145.96, for a total value of $38,601,311.40. Following the sale, the chief executive officer now directly owns 481,254 shares of the company’s stock, valued at approximately $70,243,833.84. The disclosure for this sale can be found here. In the last three months, insiders have sold 349,805 shares of company stock valued at $50,593,707. 0.22% of the stock is owned by company insiders.

JNJ stock opened at $145.99 on Monday. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.32. The company has a quick ratio of 1.40, a current ratio of 1.72 and a debt-to-equity ratio of 0.46. The stock has a market cap of $391.68 billion, a price-to-earnings ratio of 20.00, a PEG ratio of 2.28 and a beta of 0.58.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.03 by $0.02. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The firm had revenue of $20.35 billion during the quarter, compared to the consensus estimate of $20.05 billion. During the same quarter in the previous year, the business earned $1.90 earnings per share. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. On average, research analysts anticipate that Johnson & Johnson will post 8.16 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be given a dividend of $0.90 per share. This represents a $3.60 dividend on an annualized basis and a yield of 2.47%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.

JNJ has been the subject of several analyst reports. Wells Fargo & Co reiterated an “outperform” rating and issued a $160.00 target price on shares of Johnson & Johnson in a research note on Friday, September 14th. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Friday. HC Wainwright reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, October 17th. Credit Suisse Group set a $149.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, October 14th. Finally, ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $142.54.

COPYRIGHT VIOLATION NOTICE: “D.A. Davidson & CO. Has $59.81 Million Stake in Johnson & Johnson (JNJ)” was posted by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2018/11/19/d-a-davidson-co-has-59-81-million-stake-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Stock Split

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.